New cancer drug shows promise in early trial
NCT ID NCT01695005
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LY3039478 (an experimental drug taken by mouth, sometimes with prednisone)
- What this could lead to
- If it works, this could point toward a treatment option for advanced or metastatic cancers that have not responded to standard therapies.
- What could go wrong
- This is an early phase 1 trial, so the main goal is safety and dosing, not effectiveness. Many drugs fail at this stage, and side effects like heart problems or other toxicities may occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
-
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Copenhagen, 2100, Denmark
-
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Paris, 75248, France
-
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Villejuif, 94805, France
-
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tübingen, 72076, Germany
-
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Barcelona, 08035, Spain
-
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
London, SE1 9RT, United Kingdom
-
Harvard Medical School
Boston, Massachusetts, 02215, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
University of Miami School of Medicine
Miami, Florida, 33136, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a radioactive antibody light up hidden tumors?
- Could muscle loss predict blood cancer outcomes?
- A simple screening program could transform cancer aftercare
- Could a vaccine help fight Hard-to-Treat cancers?
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors